Mylan Amnesteem Has 45% Of Isotretinoin Market; Barr’s Claravis Launches
Executive Summary
Mylan's generic Accutane has captured roughly half of the isotretinoin market, the company told analysts on a first quarter conference call May 8
You may also be interested in...
Mylan Amnesteem Revenue Falls 39%, But Isotretinoin Market Share Stable
Mylan Amnesteem quarterly revenue fell by more than a third even though the acne drug's share of the isotretinoin market remains fairly stable in the face of increasing competition
Mylan Amnesteem Revenue Falls 39%, But Isotretinoin Market Share Stable
Mylan Amnesteem quarterly revenue fell by more than a third even though the acne drug's share of the isotretinoin market remains fairly stable in the face of increasing competition
Tidbits From The Fourth Quarter Calls, In Brief
AstraZeneca Prilosec generic erosion: AstraZeneca's Prilosec holds 47% share of total prescriptions following generic omeprazole entry in late 2002, CFO Jon Symonds says on Jan. 30 investor call. "We must, of course, be cautious with only six weeks of data available...but it's clear that the erosion rate is significantly less than that observed with either Prozac or Zestril at a similar stage, seemingly consistent with Kudco's inability to fully supply the market." Schwarz' subsidiary Kudco is distributing generic Prilosec on a limited basis due to supply constraints (1"The Pink Sheet" Dec. 16, 2002, p. 30)....Nexium ramp-up: Nexium total prescription share is over 20%, up more than eight percentage points in 2002. Share of total scripts written by gastrointestinal specialists is more than 27%...